Pathogenic vaginal microbiota

The pathogenic vaginal microbiota, often referred to as vaginal dysbiosis, represents a complex microbial ecosystem characterized by the loss of dominant Lactobacillus species and an overgrowth of diverse anaerobic bacteria such as Gardnerella vaginalis and Atopobium vaginae (NIH, 2023). This shift leads to an increase in vaginal pH and the production of pro-inflammatory cytokines, which are central to the pathogenesis of bacterial vaginosis (BV) and increased susceptibility to STIs like HIV (PubMed, PMID: 32451512). Unlike traditional single-protein targets, this microbial community acts as a collective therapeutic target where the goal is to disrupt pathogenic biofilms and restore a protective, lactic-acid-producing environment. Current pharmacological interventions include nitroimidazole antibiotics and lincosamides, which target anaerobic metabolism, while emerging live biotherapeutic products (LBPs) aim to re-colonize the niche with commensal strains (StatPearls, 2024). Effective management of this target is critical for reducing adverse reproductive health outcomes, including preterm labor and pelvic inflammatory disease (CDC, 2021).

Other names

Dysbiotic vaginal microbiotaVaginal dysbiosisBacterial vaginosis-associated microbiotaVaginal microbiomePolymicrobial vaginal biofilm

The mechanism of action involves the use of antibiotics to inhibit DNA synthesis or protein production in anaerobic pathogens, combined with the use of probiotics or live biotherapeutic products (LBPs) to lower vaginal pH through lactic acid production and provide competitive inhibition against pathogen colonization (PubMed, PMID: 31039281).